DDRi@CAT‐PD‐M1Exos achieved higher accumulation in tumor compared with DDRi@CAT‐M1Exos, demonstrating the affinity and in vivo tumor‐targeting ability of Anti‐PD‐L1. This evidence concerns the gene CD274 and neoplasm.